Neumora Therapeutics (NMRA) Change in Account Payables (2022 - 2026)

Neumora Therapeutics' Change in Account Payables history runs 5 years deep, the most recent figure standing at $1.7 million for Q1 2026.

• On a quarterly basis, Change in Account Payables rose 174.41% year-over-year to $1.7 million in Q1 2026; TTM through Mar 2026 was $4.0 million, a 845.62% increase from a year earlier, with the FY2025 full-year figure at $71000.0, down 97.53% from the prior year.
• Change in Account Payables fell to $1.7 million in Q1 2026 per NMRA's latest filing, from $2.8 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $7.0 million in Q2 2023 and bottomed at -$6.0 million in Q1 2023.
• The 5-year median for Change in Account Payables is -$252000.0 (2025), against an average of $66571.4.
• Across the five-year window, Change in Account Payables surged 1542.16% in 2024 and plunged 295.24% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at -$3.1 million in 2022, then soared by 38.5% to -$1.9 million in 2023, then sank by 51.52% to -$2.9 million in 2024, then soared by 197.69% to $2.8 million in 2025, then tumbled by 40.71% to $1.7 million in 2026.
• Per Business Quant, the three latest NMRA Change in Account Payables figures stand at $1.7 million (Q1 2026), $2.8 million (Q4 2025), and -$96000.0 (Q3 2025).